Telomir Pharmaceuticals annual return on equity
2023
2024
2025
Telomir Pharmaceuticals Return on Equity (ROE) Growth & History (TELO)
Telomir Pharmaceuticals's return on equity was −317.65% for fiscal 2025.
View full Telomir Pharmaceuticals company overviewTelomir Pharmaceuticals annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −317.65% | +492.53 pp |
| 2024 | 2024-12-31 | −810.18% | +235.18 pp |
| 2023 | 2023-12-31 | −1,045.36% | — |
Telomir Pharmaceuticals quarterly return on equity
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −34.45% | +3133.07 pp |
| Q1 2026 | 2026-03-31 | −18.22% | +886.40 pp |
| Q4 2025 | 2025-12-31 | −31.97% | +502.23 pp |
| Q3 2025 | 2025-09-30 | −29.55% | +549.37 pp |
| Q2 2025 | 2025-06-30 | −3,167.51% | −3107.70 pp |
| Q1 2025 | 2025-03-31 | −904.62% | −710.82 pp |
| Q4 2024 | 2024-12-31 | −534.21% | +211.69 pp |
| Q3 2024 | 2024-09-30 | −578.92% | — |
| Q2 2024 | 2024-06-30 | −59.82% | — |
| Q1 2024 | 2024-03-31 | −193.80% | — |
| Q4 2023 | 2023-12-31 | −745.90% | — |
Telomir Pharmaceuticals return on equity trends
Between the periods ended 2023-12-31 and 2025-12-31, Telomir Pharmaceuticals's return on equity increased from −1,045.36% to −317.65%, a change of +727.71 percentage points. The latest reported quarter, Q2 2026, shows −34.45%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Telomir Pharmaceuticals source filings ↗